Clinical Trials >Gyn. (Ovarian, Endometrial, Cervical) > EMR 100070-001
EMR 10070-110 - A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0010718C in subjects with metastatic or locally Multiple/All Tumor Types and expansion to selected indications.
   
1. WHAT TYPE OF CANCER? WHAT STAGE?
Stage III-IV epithelial ovarian, fallopian tube, or peritoneal cancer.
 
2. WHO IS ELIGIBLE?
Platinum-refractory (progression within 6 months of platinum-based therapy). Must have received at least 1 line of prior platinum-based chemotherapy regimen, as well as prior liposomal doxorubicin (monotherapy or combination), in order to be considered eligible for this study. May have received any additional number of prior systemic therapies for metastatic disease.
 
3. HOW WILL I BE TREATED?
MSB0010718C.
 
For Physicians: More information about this specific trial at clinicaltrials.gov.

Send an Inquiry

  • -
  • Reload
  • Should be Empty:

Disclaimer: This website is only for the purpose of sending an inquiry about a clinical trial. Your contact information will be passed our clinical trial coordinators who will pass on your contact information to the physician’s office that is sponsoring the trial that you are interested in. Entry into any clinical trial is not guaranteed – reasons for this include but are not limited to the fact that you may not be eligible, the trial may be completed or closed, or the possible treatments may not be indicated or appropriate for you.

We will attempt to contact you via your inquiry within (5) five business days, however, we cannot guarantee that you will be contacted. Though we update this website several times a year, there may be clinical trials that are not on this list or trials on this list may have closed.

This website does not is not designed to give medical advice, and does not take the place of your physician. If you have an urgent medical matter, please contact your physician or call emergency medical services.

(c) Sidd Padmanabha, M.D., and Jefferson Radiation Oncology, 2018.